01PePeptidesENHANCED

Tirzepatide available at Ascension Peptides — Save 50% with code ENHANCED

Buy Tirzepatide
TrendingCOA VerifiedInjectable

Tirzepatide

Dual GIP/GLP-1 agonist studied for metabolic health and significant weight outcomes

Half-life

~5 days

Typical Dose

2.5-15mg weekly

Format

Injectable

Purity

≥99%

Buy from Ascension — 50% off code ENHANCEDRead research

Overview

Tirzepatide is a dual receptor agonist activating both GLP-1 and GIP pathways [5]. Marketed as Mounjaro and Zepbound for diabetes and weight management. Demonstrated ~21% body weight reduction in the SURMOUNT-1 pivotal trial [1] and superior glycemic control versus semaglutide in SURPASS-2 [2]. Cardiovascular and renal benefits continue to be characterized in ongoing outcome studies [7,9].

Mechanism

First-in-class dual GIP/GLP-1 receptor agonist [5]. GIP enhances insulin response while GLP-1 reduces appetite and slows gastric emptying [6]. Together they produce stronger metabolic effects than GLP-1 alone [2,3], with biased agonism at the GLP-1 receptor that may underlie its tolerability profile [8].

Researched benefits

  • ~21% average weight reduction in clinical trials
  • Improved HbA1c and glucose control
  • Reduced cardiovascular risk markers
  • Slower gastric emptying for satiety
  • Once-weekly subcutaneous injection

Frequently asked

Tirzepatide vs Semaglutide?

Tirzepatide produces ~5-7% greater weight reduction than Semaglutide on average and shows stronger HbA1c improvements due to dual GIP/GLP-1 receptor action. The SURMOUNT-1 trial showed up to 22.5% reduction at 15mg, compared to STEP-1's ~14.9% on Semaglutide 2.4mg.

What's the half-life of Tirzepatide?

Approximately 5 days, supporting once-weekly dosing. Steady-state plasma concentrations are reached after about 4 weeks of weekly administration.

What's the typical research dose escalation?

Standard titration begins at 2.5mg weekly for 4 weeks, then increases by 2.5mg every 4 weeks as tolerated, up to maximum doses of 5mg, 10mg, or 15mg weekly. Slow titration minimizes nausea and GI side effects.

Subcutaneous vs intramuscular for Tirzepatide?

Subcutaneous administration is the only studied and recommended route. Injection sites rotate between abdomen, thigh, and upper arm. IM use has no clinical data and may alter absorption kinetics.

How is Tirzepatide reconstituted?

Bacteriostatic water is preferred for multi-use vials. For a 10mg vial, 1mL of BAC water yields 10mg/mL. Add diluent slowly down the vial wall and swirl gently — never shake. Store refrigerated.

Are there contraindications in research use?

Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent studies. It is contraindicated in subjects with personal/family history of medullary thyroid carcinoma or MEN 2. Caution with pancreatitis history and severe gastroparesis.

Scientific Literature

References

  1. [1]

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity.

    New England Journal of Medicine · PubMed: 35658024

  2. [2]

    Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

    New England Journal of Medicine · PubMed: 34170647

  3. [3]

    Rosenstock J, Wysham C, Frías JP, et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1).

    The Lancet · PubMed: 34186022

  4. [4]

    Garvey WT, Frias JP, Jastreboff AM, et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2).

    The Lancet · PubMed: 37356445

  5. [5]

    Coskun T, Sloop KW, Loghin C, et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.

    Molecular Metabolism · PubMed: 30293909

  6. [6]

    Nauck MA, Meier JJ. (2018). Incretin hormones: Their role in health and disease.

    Diabetes, Obesity and Metabolism · PubMed: 29364588

  7. [7]

    Heise T, Mari A, DeVries JH, et al. (2022). Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity.

    The Lancet Diabetes & Endocrinology · PubMed: 35468322

  8. [8]

    Willard FS, Douros JD, Gabe MB, et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.

    JCI Insight · PubMed: 32730231

  9. [9]

    Sattar N, McGuire DK, Pavo I, et al. (2022). Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.

    Nature Medicine · PubMed: 35551291

  10. [10]

    Wilding JPH, Batterham RL. (2023). Long-term effects of incretin-based therapies on body weight.

    Journal of Clinical Endocrinology & Metabolism · PubMed: 37410391

  11. [11]

    Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4).

    JAMA · PubMed: 38078870

Citations are provided for educational purposes. Always verify primary sources before drawing research conclusions.

Ready to start your research

Get Tirzepatide from Ascension Peptides

COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.

Buy Tirzepatide now